An international team of researchers has created a genome-scale map of 26 different cancers, revealing more than 100 genomic sites where DNA from tumors is either missing or abnormally duplicated compared to normal tissues. The study, the largest of its kind, finds that most of these genetic abnormalities are not unique to one form of cancer, but are shared across multiple cancers. The work appears in the February 18 issue of the journal Nature.
"Our findings show that many genome alterations are universal across different cancers. Although this has been known for some types of changes, the degree to which so many alterations are shared was pretty surprising to us," said senior author Matthew Meyerson, a professor of pathology at the Dana-Farber Cancer Institute and senior associate member of the Broad Institute of Harvard and MIT. "It suggests that, in the future, a driving force behind cancer treatment will be common genomic alterations, rather than tumors' tissue of origin."
Today, cancers are characterized largely by their symptoms: the organ in the body in which they first arise and the appearance of tumor cells under a microscope. Although this information is valuable, it fails to highlight cancers' molecular underpinnings, which could be used in the laboratory to discover new, more effective cancer therapies and in the clinic to improve diagnosis and treatment. A goal of modern biomedical research is to fill this knowledge gap and describe all cancers based on what drives them -- that is, the genetic aberrations that initiate and maintain tumor growth.
In 2004, a scientific team led by researchers at the Dana-Farber and the Broad Institute launched a project to systematically map the genetic changes across different cancers. They focused on a particular type of DNA change in which segments of a tumor's genome are present in abnormal copies. Instead of the usual two copies, tumors often carry several copies of one piece of DNA (an "amplification") or may lack it altogether (a "deletion"). These genetic abnormalities are known as somatic copy-number alterations or SCNAs.
Like other types of DNA mutations that litter the genomes of tumor cells, most SCNAs do not necessarily play a meaningful role in cancer growth. But the ones that do serve as important signposts, pointing to the specific genes contained within them that help promote and maintain cancers. The challenge lies in distinguishing these so-called drivers from their less influential counterparts.
As the foundation for their analysis, the scientists collected over 2,500 cancer specimens representing more than two dozen cancer types, including lung, prostate, breast, ovarian, colon, esophageal, liver, brain and blood cancers.
"Studies like this require a large and diverse group of tumor specimens," said first author Rameen Beroukhim, an assistant professor of medical oncology at Dana-Farber Cancer Institute and a researcher at the Broad Institute. "We are deeply grateful to our collaborators and to their patients who generously shared samples with us."
Using powerful genomic "chip" technologies, the researchers analyzed DNA from these samples, and combined their data with publicly available data from another 600 tumor samples to assemble a detailed catalogue of the SCNAs present in multiple tumor types. They found that the most common SCNAs tend to come in two sizes: relatively long, about the length of an entire chromosome or a single chromosome arm, and short, with an average size of about 1.8 million genetic letters or 0.03% of the entire human genome.
The researchers focused their attention on the short or focal SCNAs, which, due to their relatively compact size, can facilitate the task of pinpointing important cancer genes.
"Until recently, the analytic methods needed to support this kind of analysis were not available," said first author Craig Mermel, an M.D./Ph.D. student working in Meyerson's laboratory and at the Broad Institute. "New advances by our group as well as many others have now made it feasible to systematically map genomic changes across thousands of samples and at high resolution."
Of the 150 or so focal SCNAs they identified, Meyerson and his colleagues noticed that the majority did not coincide with genes already known to be amplified or deleted in cancer. Looking more closely at the genes that normally reside in these regions, the researchers found an enrichment of genes with important biological functions in cancer, such as cell death (or "apoptosis").
This analysis helped shed light on two genes, MCL1 and BCL2L1. Cancer cells with amplifications of these genes appear to rely on the genes' activity for survival, suggesting important roles in maintaining tumor growth.
Perhaps most importantly, looking across the data for the various cancers, it became clear that most focal SCNAs are not unique to just one type of cancer, but are shared among multiple tumor types. In an analysis of 17 different cancer types, the researchers found that a majority of amplifications and deletions are present in more than one type.
That suggests the genetic mechanisms that underlie these tumors are shared among them, and could someday lead to common strategies for treating them.
"These data signify an important resource for cancer gene discovery, but they're only a first step," said Meyerson. "With the ongoing revolution in genome technology, it will become possible to decode the genomes of thousands of cancers to reveal every genomic change."
The Nature study was supported by the National Institutes of Health, the Doris Duke Charitable Foundation, the Sarah Thomas Monopoli Lung Cancer Research Fund, the Seaman Corporation Fund for Lung Cancer Research, and the Lucas Foundation.
Data from the Nature paper are freely available at http://www.
Beroukhim et al. The landscape of somatic copy-number alteration across human cancers. Nature DOI: 10.1038/nature08822
About the Broad Institute of MIT and Harvard
The Eli and Edythe L. Broad Institute of MIT and Harvard was founded in 2003 to empower this generation of creative scientists to transform medicine with new genome-based knowledge. The Broad Institute seeks to describe all the molecular components of life and their connections; discover the molecular basis of major human diseases; develop effective new approaches to diagnostics and therapeutics; and disseminate discoveries, tools, methods and data openly to the entire scientific community.
Founded by MIT, Harvard and its affiliated hospitals, and the visionary Los Angeles philanthropists Eli and Edythe L. Broad, the Broad Institute includes faculty, professional staff and students from throughout the MIT and Harvard biomedical research communities and beyond, with collaborations spanning over a hundred private and public institutions in more than 40 countries worldwide. For further information about the Broad Institute, go to www.broadinstitute.org.
About Dana-Farber Cancer Institute
Dana-Farber Cancer Institute (www.dana-farber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute. It is the top ranked cancer center in New England, according to U.S. News & World Report, and one of the largest recipients among independent hospitals of National Cancer Institute and National Institutes of Health grant funding.
For more information, contact:
Broad Institute of MIT and Harvard
Dana-Farber Cancer Institute